Vanda Pharmaceuticals Reports First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500, Nasdaq climb as soft inflation dampens Fed rate hike expectations
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise by about $1/bbl on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 flat as higher bond yields counter tech optimism
Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 12c
May 5, 2022 5:05 PM EDTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of $0.11, $0.12 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $60.2 million versus the consensus estimate of $58 million.
Cash, cash equivalents and marketable securities (Cash) was $435.2 million as of March 31, 2022, representing an increase to... More
